Retatrutide Triple Agonist Guide

If you have been following the GLP-1 space, you have probably heard the buzz around retatrutide. This investigational drug is being called a potential turning point in weight management. And for good reason. This retatrutide guide breaks down everything you need to know about the triple-agonist medication, including how it works, what clinical trials have shown, and when it might become available. If you're already using a GLP-1 medication or just exploring your options, this is a drug worth understanding.

Key Takeaways: - Understand what makes retatrutide different from other glp-1 drugs - Understand what did the phase 2 clinical trials show - When Will Retatrutide Be Available - Learn how does the glucagon receptor fit into weight loss - Understand what this means for your weight loss

What Makes Retatrutide Different From Other GLP-1 Drugs?

Most GLP-1 medications work by targeting a single receptor. Semaglutide, for example, activates the GLP-1 receptor. Tirzepatide targets two receptors: GLP-1 and GIP. Retatrutide goes a step further. It targets three receptors at once: GLP-1, GIP, and glucagon.

This is why researchers call it a "triple agonist." Each of those three hormone pathways plays a role in how your body manages weight, blood sugar, and energy.

The GLP-1 receptor helps control appetite and slows stomach emptying. When activated, it signals your brain that you're full. It also helps regulate blood sugar by prompting insulin release when glucose levels rise.

The GIP receptor plays a role in insulin secretion and fat metabolism. GIP stands for glucose-dependent insulinotropic polypeptide. Current Available data suggest that GIP activation may enhance the effects of GLP-1, which is why tirzepatide (a dual GLP-1/GIP agonist) tends to produce greater weight loss than semaglutide alone.

The glucagon receptor increases energy expenditure and helps your body burn stored fat. This is the component that truly sets retatrutide apart from every other obesity medication in development. Glucagon tells your liver to release stored glucose and promotes the breakdown of fat cells for energy.

By activating all three pathways, retatrutide may produce stronger effects than drugs that target only one or two. Think of it like this: instead of pressing one lever for weight management, your body is working three levers at once. You eat less, metabolize fat more efficiently, and burn more calories even at rest.

Retatrutide is administered as a once-weekly subcutaneous injection, similar to semaglutide and tirzepatide. The dosing schedule makes it convenient. In clinical trials, the dose was gradually increased over several weeks to help minimize side effects.

If you're curious how existing GLP-1 medications compare to each other, our is a great starting point.

"The key to successful GLP-1 therapy is setting realistic expectations and supporting patients through the titration phase. The side effects are manageable for most people, but they need to know what to expect.") Dr. Caroline Apovian, MD, Harvard Medical School

What Did the Phase 2 Clinical Trials Show?

The phase 2 trial results for retatrutide grabbed attention across the medical world. Published in the New England Journal of Medicine in 2023, the trial enrolled nearly 340 adults with obesity or overweight with at least one weight-related condition.

The results were striking. Participants on the highest dose of retatrutide lost an average of approximately 24% of their body weight over 48 weeks. That's among the highest weight loss percentages seen in any clinical trial for an anti-obesity medication.

For context, phase 3 clinical trials for semaglutide showed average weight loss of about 15% of body weight. Tirzepatide trials showed around 20-22%. Retatrutide's phase 2 numbers suggest it may outperform both, though phase 3 trials are still needed to confirm these results in larger populations.

Side effects in the trial were similar to other GLP-1 medications. Nausea, diarrhea, and vomiting were the most common. These were mostly mild to moderate and tended to decrease over time, especially with gradual dose escalation.

Phase 2 trials involve smaller groups of people. Phase 3 results, which study thousands of participants, will give a clearer picture of both effectiveness and safety.

The trial also looked at metabolic health markers beyond weight. Participants showed improvements in blood sugar control, insulin sensitivity, and lipid levels. Some participants experienced reductions in liver fat that could have implications for treating fatty liver disease.

Researchers noted that weight loss was still trending downward at the end of the 48-week study, meaning participants had not yet reached a plateau. This suggests that longer treatment could produce even greater results. The phase 3 trials are expected to run for longer durations, which will help answer that question.

Free Download: GLP-1 Medication Comparison One-Pager See how retatrutide stacks up against semaglutide, tirzepatide, and other GLP-1 options in one easy reference sheet. Get yours free -- we'll email it to you instantly. [Email Input] [Download Button]

When Will Retatrutide Be Available?

Retatrutide is being developed by Eli Lilly, the same company behind tirzepatide. As of early 2026, phase 3 clinical trials are underway. These large-scale studies are testing retatrutide for both obesity and type 2 diabetes. Eli Lilly is running multiple phase 3 trials under the TRIUMPH program name, enrolling thousands of participants across different populations.

Based on current timelines, most analysts expect an FDA submission sometime in late 2026 or 2027. If approved, retatrutide could reach the market by 2027 or 2028. But drug development timelines can shift depending on trial results and regulatory decisions.

There are a few things to watch for. The FDA will want to see consistent results across a large and diverse population. They will also evaluate the safety profile carefully, especially regarding the glucagon receptor component, which is newer territory for weight management drugs.

Eli Lilly has a strong track record of dealing with FDA approvals. They successfully brought tirzepatide to market for both diabetes (as Mounjaro) and obesity (as Zepbound). That experience may help simplify the regulatory process for retatrutide. The company has also invested heavily in manufacturing capacity, which could help avoid the supply shortages that have affected other GLP-1 medications.

It's also retatrutide is being studied for additional indications beyond obesity and diabetes. Research is examining its potential benefits for metabolic dysfunction-associated steatotic liver disease (MASLD), sleep apnea, and cardiovascular disease. If these studies pan out, retatrutide could receive multiple FDA approvals over time.

Until retatrutide becomes available, many people are finding effective treatment with currently available GLP-1 medications. If you're interested in exploring your options today, you can about personalized compounded medications prepared by a licensed US-based 503A pharmacy.

How Does the Glucagon Receptor Fit Into Weight Loss?

The glucagon component is what really sets retatrutide apart. Glucagon has traditionally been associated with raising blood sugar, which might sound counterproductive for weight management. But research has shown that glucagon receptor activation also increases energy expenditure.

In simple terms, activating the glucagon receptor may help your body burn more calories at rest. It can also promote the breakdown of fat stores in the liver, which is why retatrutide is also being studied for metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as fatty liver disease.

The combination of reduced appetite (from GLP-1), improved fat metabolism (from GIP), and increased energy burning (from glucagon) creates a multi-pronged approach. Studies suggest this combination may be why the weight loss numbers in clinical trials have been so impressive.

This triple mechanism also raises hope that retatrutide could help with weight loss maintenance, one of the biggest challenges in obesity treatment. By addressing multiple metabolic pathways, it may help prevent the metabolic slowdown that often occurs during weight loss.

The liver health angle is especially promising. Non-alcoholic fatty liver disease affects an estimated 80-100 million Americans. Many of them also have obesity. A single medication that addresses both conditions could be enormously valuable. Early data from retatrutide trials showed liver fat reductions of more than 80% in some participants, which is remarkable.

Researchers are also studying whether the glucagon component affects body composition differently than GLP-1-only drugs. Some early Available data suggest that glucagon receptor activation may preferentially target visceral fat, the dangerous fat that wraps around your internal organs. Reducing visceral fat is linked to lower risk of heart disease, diabetes, and certain cancers.

For a deeper understanding of how these different hormone targets work together, check out our .

What This Means for your treatment

Retatrutide represents the next wave of obesity treatment. But waiting for a future drug isn't your only option. The GLP-1 medication market already offers effective treatments that are available right now.

Compounded semaglutide and tirzepatide are currently accessible through licensed telehealth providers. These medications contain compounded formulations of the active ingredient found in brand-name versions and are prepared by licensed US-based 503A compounding pharmacies.

If retatrutide does receive FDA approval, it will likely expand the range of options even further. More options mean more personalized treatment, which is always a good thing. Your provider can help you understand which medication might work best for your specific health profile.

The growing number of GLP-1 options also creates healthy competition in the market. More drugs competing for patients may lead to lower prices, better insurance coverage, and more accessible treatment overall. That benefits everyone, whether you choose to use a newer drug or stick with a proven option.

For now, the most important step is starting the conversation with a licensed provider. They can evaluate your health history, discuss your goals, and recommend a treatment plan based on what is available today. As newer medications reach the market, you and your provider can revisit those options together.

If you're managing side effects on your current GLP-1 medication, our covers practical strategies that may help.

Want to know if you might be a candidate for GLP-1 treatment? Our takes just two minutes and can help you understand your options.

Frequently Asked Questions

Is retatrutide approved by the FDA?

No, retatrutide isn't yet FDA-approved. It's currently in phase 3 clinical trials. If trials are successful, it could receive FDA approval and reach the market by 2027 or 2028.

How much weight can you lose on retatrutide?

In phase 2 clinical trials, participants on the highest dose lost an average of approximately 24% of their body weight over 48 weeks. But individual results vary, and phase 3 trial data is needed to confirm these findings in larger populations.

What are the side effects of retatrutide?

The most common side effects reported in clinical trials were gastrointestinal, including nausea, diarrhea, and vomiting. These were mostly mild to moderate and tended to improve over time with gradual dose increases. A full safety profile will come from ongoing phase 3 trials.

How is retatrutide different from tirzepatide?

Tirzepatide is a dual agonist that targets GLP-1 and GIP receptors. Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors. The additional glucagon receptor activation may increase energy expenditure and fat burning, potentially leading to greater weight loss.

Can I get retatrutide through FormBlends?

Retatrutide isn't currently available as it's still in clinical trials. FormBlends offers compounded semaglutide and tirzepatide through licensed providers. You can while monitoring retatrutide's progress toward approval.

What's Your Next Move?

You have the information. Now let a licensed provider help you put it into action. FormBlends makes it simple, answer a few questions and get a personalized recommendation.

Sources &. References

1. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
2. Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
4. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
5. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
6. Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
9. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2^[4] (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
10. Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3^[5] (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
11. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4^[6] (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
12. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881

The information in this article is intended for educational use only and shouldn't be considered medical advice. Consult a qualified healthcare provider before making any changes to your medication or supplement regimen. FormBlends helps with connections with licensed providers for personalized medical guidance.

Last updated: 2026-03-24